Clinical Trial Update: High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for high-risk recurrent or second primary head and neck cancer using a PD-1 antibody as adjuvant after salvage surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Cancer | Phase 2 | Status: UNKNOWN